Organization
Genome & Company
4 clinical trials
Clinical trial
A Phase I Study to Evaluate the Safety and Tolerability of GENA-104A16 (Anti-contactin4 [CNTN4] Monoclonal Antibody [mAb]) in Patients With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase II Study to Evaluate the Safety and the Efficacy of GEN-001 in Combination With Pembrolizumab for Patients With Advanced Refractory Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination With Avelumab in Patients With Advanced Solid Tumors Who Have Progressed During or After Treatment With Anti-PD-(L)1 TherapyStatus: Completed, Estimated PCD: 2023-01-11
Clinical trial
A Phase II Study to Evaluate the Safety and the Efficacy of GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Advanced Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01